Diagnostic Imaging's Weekly Scan: September 18-September 24

Diagnostic Imaging's Weekly Scan is your chance to catch up on the latest radiology content, from new research and device news to the latest case quizzes and conference reports. Review the slideshow below to see this week's top content:

Diagnostic Imaging's Weekly Scan: September 18-September 24

Click the arrows above to view top radiology content from the past week.

New Mammography Study Examines Association Between Breast Density Changes and Breast Cancer Risk

In a retrospective review involving over 2.2 million women with three consecutive binennial mammography screenings and no history of breast cancer, researchers noted that for premenopausal women with fatty breasts at baseline, increasing breast density at subsequent screenings led to significantly elevated hazard ratios ranging from 1.45 to 1.93 for the risk of breast cancer. READ MORE

FDA Approves New MRI Contrast Agent Gadopiclenol

Requiring only half of the gadolinium dose of current non-specific gadolinium-based contrast agents (GBCAs), gadopiclenol can be utilized with magnetic resonance imaging (MRI) to help detect lesions with abnormal vascularity in the central nervous system and other areas of the body. READ MORE

Five Takeaways from New Consensus Recommendations for CT Imaging and Reporting in Patients with CAD

In an update of the original CAD-RADS™ consensus documnent on coronary artery disease (CAD) imaging and reporting published in 2016, expert panelists incorporated emerging evidence for CAD-RADS 2.0 to recommend new categorization for coronary plaque burden and suggested modifiers to reflect the level of ischemia and high-risk plaque in patients undergoing cardiac computed tomography. READ MORE

Study Shows Adjunctive Benefit of Pre-Biopsy MRI for Diagnosing Prostate Cancer

Emerging research suggests that combining pre-biopsy magnetic resonance imaging (MRI) with prostate-specific antigen (PSA) testing more than triples the specificity rate for detecting clinically significant prostate cancer in comparison to sole reliance on a PSA level greater than or equal to 4 ng/mL. READ MORE

New Version of Adjunctive MRI Neuroimaging Software Gets FDA Nod

Version 2.1 of the ClearPoint Neuro Navigation software reportedly offers enhanced imaging and new trajectory planning tools for neurosurgical procedures. READ MORE

PreviousNext